Pasar al contenido principal

ESTRATEGIAS TERAPEUTICAS INNOVADORAS EN NEUROLOGIA: AGENTES NEUROREPARADORES Y FOTOMODULABLES

PID2021-122650OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

8-Amide and 8-carbamate substitution patterns as modulators of 7-hydroxy-4-methylcoumarin's antidepressant profile: Synthesis, biological evaluation and docking studies

  • Matos, Maria João Correia Pinto Carvalho de
  • Novo, Paula
  • Mayán Santos, Lucía
  • Torres, Iria
  • Uriarte Villares, Eugenio
  • Yáñez Jato, Matilde
  • Ortuso, Francesco
  • Alcaro, Stefano
  • Procopio, Francesca
  • Rodríguez Franco, María Isabel
  • Val García, Cristina
  • Loza García, María Isabel
  • Brea Floriani, José Manuel
  • Borges, Fernanda
  • Viña Castelao, María Dolores
  • Fontenla Gil, José Ángel
Psychiatric and neurological disorders affect millions of people worldwide. Currently available treatments may help to improve symptoms, but they cannot cure the diseases. Therefore, there is an urgent need for potent and safe therapeutic solutions. 8-Amide and 8-carbamatecoumarins were synthetized and evaluated as human monoamine oxidase A and B (hMAO-A and hMAO-B) inhibitors. Comparison between both scaffolds has been established, and we hypothesized that the introduction of different substituents can modulate hMAO activity and selectivity. N-(7-Hydroxy-4-methylcoumarin-8-yl)-4-methylbenzamide (9) and ethyl N-(7-hydroxy-4-methylcoumarin-8-yl)carbamate (20) proved to be the most active and selective hMAO-A inhibitors (IC50 = 15.0 nM and IC50 = 22.0 nM, respectively), being compound 9 an irreversible hMAO-A inhibitor twenty-four times more active in vitro than moclobemide, a drug used in the treatment of depression and anxiety. Based on PAMPA assay results, both compounds proved to be good candidates to cross the blood-brain barrier. In addition, these compounds showed non-significant cytotoxicity on neuronal viability assays. Also, the best compound proved to have a t1/2 of 6.84 min, an intrinsic clearance of 195.63 μL min−1 mg−1 protein, and to be chemically stable at pH 3.0, 7.4 and 10.0. Docking studies were performed to better understand the binding affinities and selectivity profiles for both hMAO isoforms. Finally, theoretical drug-like properties calculations corroborate the potential of both scaffolds on the search for new therapeutic solutions for psychiatric disorders as depression
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

KEAP1-NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential

  • Crisman, Enrique
  • Duarte, Pablo
  • Dauden, Esteban
  • Cuadrado, Antonio
  • Rodríguez-Franco, María Isabel
  • López, Manuela G.
  • León, Rafael
The transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is considered the master regulator of the phase II antioxidant response. It controls a plethora of cytoprotective genes related to oxidative stress, inflammation, and protein homeostasis, among other processes. Activation of these pathways has been described in numerous pathologies including cancer, cardiovascular, respiratory, renal, digestive, metabolic, autoimmune, and neurodegenerative diseases. Considering the increasing interest of discovering novel NRF2 activators due to its clinical application, initial efforts were devoted to the development of electrophilic drugs able to induce NRF2 nuclear accumulation by targeting its natural repressor protein Kelch-like ECH-associated protein 1 (KEAP1) through covalent modifications on cysteine residues. However, off-target effects of these drugs prompted the development of an innovative strategy, the search of KEAP1-NRF2 protein–protein interaction (PPI) inhibitors. These innovative activators are proposed to target NRF2 in a more selective way, leading to potentially improved drugs with the application for a variety of diseases that are currently under investigation. In this review, we summarize known KEAP1-NRF2 PPI inhibitors to date and the bases of their design highlighting the most important features of their respective interactions. We also discuss the preclinical pharmacological properties described for the most promising compounds., Enrique Crisman is the recipient of a PFIS fellowship of ISCIII. Pablo Duarte is the recipient of an FPU fellowship of the Spanish Ministry of education. Authors gratefully acknowledge funding from IS Carlos III, Comunidad de Madrid, and Spanish Research Agency. We thank Fundación Teófilo Hernando for its continued support. All schemes were created with Biorender.com. IS Carlos III cofinanced by the European Regional Development funds (FEDER) grant number PI17/01700. General Council for Research and Innovation of the Community of Madrid and European Structural Funds (grant B2017/BMD‐3827 NRF24ADCM. Spanish Ministry of Science, Innovation and Universities (grants PID2021‐123481OB‐I00, PID2021‐122650OB‐I00, PID2021‐125986OB‐I00, PDC2021‐121421‐I00, and PID2019‐110061RB‐I00). The authors have no financial support to disclose., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

8-Amide and 8-carbamate substitution patterns as modulators of 7-hydroxy-4-methylcoumarin's antidepressant profile: Synthesis, biological evaluation and docking studies

  • Matos, María de Jesús
  • Novo, Paula
  • Mayán, Lucía
  • Torres, I.
  • Uriarte, Eugenio
  • Yáñez, Matilde
  • Fontenla, José Ángel
  • Ortuso, F.
  • Alcaro, Stefano
  • Procopio, Francesca
  • Rodríguez-Franco, María Isabel
  • Val, Cristina
  • Loza, María Isabel
  • Brea, José Manuel
  • Borges, Fernanda
  • Viña, Dolores
Psychiatric and neurological disorders affect millions of people worldwide. Currently available treatments may help to improve symptoms, but they cannot cure the diseases. Therefore, there is an urgent need for potent and safe therapeutic solutions. 8-Amide and 8-carbamatecoumarins were synthetized and evaluated as human monoamine oxidase A and B (hMAO-A and hMAO-B) inhibitors. Comparison between both scaffolds has been established, and we hypothesized that the introduction of different substituents can modulate hMAO activity and selectivity. N-(7-Hydroxy-4-methylcoumarin-8-yl)-4-methylbenzamide (9) and ethyl N-(7-hydroxy-4-methylcoumarin-8-yl)carbamate (20) proved to be the most active and selective hMAO-A inhibitors (IC = 15.0 nM and IC = 22.0 nM, respectively), being compound 9 an irreversible hMAO-A inhibitor twenty-four times more active in vitro than moclobemide, a drug used in the treatment of depression and anxiety. Based on PAMPA assay results, both compounds proved to be good candidates to cross the blood-brain barrier. In addition, these compounds showed non-significant cytotoxicity on neuronal viability assays. Also, the best compound proved to have a t of 6.84 min, an intrinsic clearance of 195.63 μL min mg protein, and to be chemically stable at pH 3.0, 7.4 and 10.0. Docking studies were performed to better understand the binding affinities and selectivity profiles for both hMAO isoforms. Finally, theoretical drug-like properties calculations corroborate the potential of both scaffolds on the search for new therapeutic solutions for psychiatric disorders as depression., This research was funded by Consellería de Cultura, Educacion ´ e Ordenacion ´ Universitaria (EM2014/016), Ministerio de Ciencia e Innovacion ´ (PID2020-116076RJ-I00/AEI/10.13039/501100011033) and Fundaçao ˜ para a Ciˆencia e Tecnologia (PTDC/ASP-PES/28397/ 2017, CEECIND/02423/2018, UIDB/00081/2020, LA/P/0056/2020 and EXPL/BIA-BQM/0492/2021). Financial support from the Xunta de Galicia (Centro de investigacion ´ de Galicia accreditation 2019–2022) and the European Union (European Regional Development Fund - ERDF), is also gratefully acknowledged. M.I.R.-F. acknowledges the economic support from the Spanish Ministry of Science, Innovation and Universities; Spanish Research Agency; and European Regional Development Funds (grant PID2021-122650OB-I00) and from CSIC (PIE202080E118).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovery of a potent melatonin-based inhibitor of quinone reductase-2 with neuroprotective and neurogenic properties

  • Herrera-Arozamena, Clara
  • Estrada-Valencia, Martín
  • García-Díez, Guillermo
  • Pérez, Concepción
  • León, Rafael
  • Infantes, Lourdes
  • Morales-García, José A.
  • Pérez-Castillo, Ana
  • Sastre, Eric del
  • López, Manuela G.
  • Rodríguez-Franco, María Isabel
5-Methoxy-3-(5-methoxyindolin-2-yl)-1H-indole (3), whose structure was unambiguously elucidated by X-ray analysis, was identified as a multi-target compound with potential application in neurodegenerative diseases. It is a low nanomolar inhibitor of QR2 (IC50 = 7.7 nM), with greater potency than melatonin and comparable efficacy to the most potent QR2 inhibitors described to date. Molecular docking studies revealed the potential binding mode of 3 to QR2, which explains its superior potency compared to melatonin. Furthermore, compound 3 inhibits hMAO-A, hMAO-B and hLOX-5 in the low micromolar range and is an excellent ROS scavenger. In phenotypic assays, compound 3 showed neuroprotective activity in a cellular model of oxidative stress damage, it was non-toxic, and was able to activate neurogenesis from neural stem-cell niches of adult mice. These excellent biological properties, together with its both good in silico and in vitro drug-like profile, highlight compound 3 as a promising drug candidate for neurodegenerative diseases., Theauthors gratefully acknowledge the following financial supports: Spanish Ministry of Science, Innovation and Universities; Spanish Research Agency; and European Regional Development Funds (grants PID2021-122650OB-I00 to M.I.R.-F.; PDC2022-133809-I00 to M.G.L., R.L., and M.I.R.-F.; PID2021-123481OB-I00 to R.L.; PID2021125986OB-I00 to M.G.L.; PID2020-117400 GB-I00 to L.I.); General Council for Research and Innovation of the Community of Madrid (grant P2022/BMD-7230 to M.G.L., R.L., and M.I.R.-F.); Spanish National Research Council (CSIC, grant PIE-202480E175 to M.I.R.-F.) Compound 3 X-ray experiments were performed at BL13-XALOC beamline at ALBA Synchrotron with the collaboration of ALBA staff. We thank the Spanish Ministry of Science, Innovation and Universities for the fellowships FPU22/03672 to G.G.-D. and FPU18/00630 to E.dS. The authors acknowledge the support of the European COST Action CA20121 (BenBedPhar) and the Fundación Teófilo Hernando, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Target Fisher: A Consensus Structure-Based Target Prediction Tool, and its Application in the Discovery of Selective MAO-B Inhibitors

  • Fernández, Julián F.
  • Martinez Heredia, Leandro
  • Caracciolo, Fernando
  • Esses, Daniel
  • Suarez, Rodrigo
  • Siless, Gaston
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel
  • Fernández, Lucía R.
  • Palermo, Jorge A.
  • Lavecchia, Martín
In this work we introduce Target Fisher, a consensus structure-based target prediction tool that integrates molecular docking and machine learning with the aim to aid in the identification of potential biological targets and the optimization of the use of bioassays. Target Fisher uses per-residue energy decomposition profiles extracted from docking poses as fingerprints to train target-specific machine learning models. It provides predictions for a curated set of 37 protein targets, covering a diverse range of biological entities, and offers a user-friendly interface accessible via a web server (https://gqc.quimica.unlp.edu.ar/targetfisher/). In this sense, Target Fisher is a valuable tool to aid organic and medicinal chemistry groups in target identification, drug discovery and drug repurposing. As a case study, we demonstrate the efficacy of Target Fisher by screening a small library of assorted natural products for targets relevant to neurodegenerative diseases, which resulted in the identification and experimental validation of selective inhibitors of monoamine oxidase B (MAO−B)., This work was supported by grants (to JAP) from CONICET (PIP N° 11220130100523CO and 11220200101898CO), UBA (UBACyT 2018 N° 20020170100509BA) and ANPCyT (PICT-2018-00930 and PICT-2021-00412). MIRF thanks the Spanish Research Agency for grant PID2021-122650OB, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel potent and selective dual acetylcholinesterase inhibitors: N-substituted theobromine and theophylline derivatives

  • Biscussi, Brunella
  • Cueto-Díaz, Eduardo J.
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel
  • Paula Murray, Ana
Methylxanthines and their derivatives are of great interest due to their diverse biological activities. In this work, a new series of twenty-eight semisynthetic theobromine and theophylline derived compounds were designed and synthesized by applying a simple and efficient strategy. First, the corresponding methylxanthine was reacted with a dibromoalkane (n = 3, 5-8) and subsequently, the brominated intermediate was reacted with an amine, including pyrrolidine, piperidine, diethylamine, methylpiperazine, 1-(2-aminoethyl)pyrrolidine, 1-(2-aminoethyl)piperidine, 2-(1-methylpyrrolidin-2-yl)ethanamine, 1-benzylpiperidin-4-amine, 1-benzylpiperidin-4-yl-methanamine, and 2-(1-benzylpiperidin-4-yl)ethan-1-amine. The two synthetic steps were carried out in very short times using a microwave reactor. The biological activity of the new compounds was evaluated on acetylcholinesterase (AChE), butyrylcholinesterase (BChE), monoamine oxidases (MAO-A, MAO-B) and beta-secretase (BACE-1). The majority of the new derivatives showed potent and selective in vitro AChE inhibition. Compounds 21, 28 and 30 exhibited the strongest effect on both electric eel and human AChE enzyme, with IC50 values on the low nanomolar scale. The kinetic study of compound 28 in hAChE displayed a mixed inhibition mechanism, suggesting a simultaneous interaction with both the CAS and PAS of the enzyme. This experimental binding mode is consistent with the results of docking and molecular dynamics modelling studies, where it was observed that the piperidinium fragment of 16, 21, 28 and 32 was located at the CAS, whereas the xanthine fragment of each inhibitor interacted with Trp286 in the PAS. These results indicate that these novel xanthine analogues act as selective and potent AChE inhibitors that could also prevent the precipitation of the aberrant Aβ peptide. These properties, in conjunction with their in silico good pharmacokinetic profiles, make these molecules promising lead compounds for the development of new effective drugs against several forms of dementia., M. I. R.-F. gratefully acknowledges the financial support from the following: the Spanish Ministry of Science, Innovation and Universities, Spanish Research Agency, and European Regional Development Funds (grant PID2021-122650OB-I00), the General Council for Research and Innovation of the Community of Madrid (grant P2022/BMD-7230), and the Spanish National Research Council (CSIC, grant PIE202480E175). A. P. M. acknowledges the financial support received from the National Scientific and Technical Research Council (CONICET grant PIP2021 GI 11220200100834CO), the National Agency for Promotion of Science and Technology (ANPCyT grant PICT2020-01187) and Universidad Nacional del Sur (grant PGI-UNS 24/Q141), from Argentina. B. B. expresses her gratitude to CONICET for her postdoctoral fellowship and to Fundación Carolina (Spain) and the Ministry of Education of Argentina for funding her threemonth research stay at IQM, Madrid, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New Tacrine Dimers Alleviate the Intracellular Amyloid-β-induced Cognitive Disturbance and Oxidative Stress in Mice

  • Gonçalves, Ana Elisa
  • Spigariol, Otto
  • Da Silva, Luísa M.
  • Rego, Yuri F.
  • Herrera-Arozamena, Clara
  • Rodríguez-Franco, María Isabel
  • De Fátima, Ângelo
  • Doring, Thiago Henrique
  • Araujo, Lucas Augusto
  • Macedo, Maria Lígia R
  • Saba, Sumbal
  • Rafique, Jamal
  • De Oliveira, Aldo S.
  • De Souza, Márcia Maria
This study aimed to investigate <italic>in vivo</italic> and <italic>ex-vivo</italic> the effects of tacrine dimers (TD1, TD2, TD3 and TD4) in mice with Alzheimer's disease (AD) induced by amyloid peptide (A<italic>β</italic>42) and, respectively, evaluated in behavioral tests of cognition, oxidative stress and neuroinflammation. All dimers reduced the cognitive deficit caused by A<italic>β</italic>42, oxidative stress and neuroinflammation, especially the compound TD4. By ADMET analysis (SwissADME and pkCSM 2.10 platforms), TD4 exhibited favorable pharmacokinetic properties with the control drug. The results suggest a therapeutic potential for AD for these compounds, given their distinct cognitive and neuroprotective effects in AD models induced by A<italic>β</italic>42., This work was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Ensino Superior (CAPES, Finance code 001), Fundação de Amparo à Pesquisa de Santa Catarina (FAPESC) and Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG). S.S. and J.R. would also like to acknowledge CNPq (grant: 316687/2023-5, 309975/2022-0, 404172/2023-7, 405655/2023-1). S.S. would also like to acknowledge Este artículo se trata de una colaboración con investigadores de la Universidad de Florencia. Han sido ellos quienes se han encargado de pagar las tasas del OA. Creo que también tenían acuerdo con ACS. Un saludo, (04/2023; EQU2023101000020). S.S. would also like to acknowledge FAPEG (04/2023; EQU2023101000020). Partial support was provided by the Spanish Ministry of Science, Innovation and Universities; Spanish Research Agency; and European Regional Development Funds (grant PID2021-122650OB-I00) to M.I.R.-F., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Long-term NRF2-driven microglial repopulation mitigates microgliosis, neuronal loss and cognitive deficits in tauopathy

  • Viqueira, Lucía
  • Navarro, Elisa
  • Negredo, Pilar
  • Bernal, Juan Antonio
  • Rodríguez-Franco, María Isabel
  • Tortosa, Elena
  • López, Manuela G
Tauopathies, including Alzheimer's disease, feature chronic microglial reactivity that drives neuroinflammation and disease progression. Pharmacological microglial depletion and subsequent repopulation using colony-stimulating factor 1 receptor inhibitors have emerged as a potential therapeutic strategy to reprogram dysfunctional microglia. Despite promising short-term results, the long-term efficacy and pharmacological modulation of repopulated microglia remain poorly understood. Here, we investigated the long-term effects of microglial repopulation alone and in combination with the activation of the cytoprotective nuclear factor erythroid 2 p45-related factor 2 (NRF2) in an in vivo AAV-hTauP301L induced model. Integrating different behavioural, immunohistological and transcriptomic analysis, we evaluated cognitive function, tau pathology, neuronal survival and glial reactivity. We found that, whereas microglial repopulation alone did not significantly affect disease progression, NRF2-driven microglial replenishment sustained cognitive function, prevented hippocampal neuronal loss and restored microglial phenotype. Transcriptomic analyses further revealed that the combined treatment modulated tau- associated mitochondrial gene expression changes. These results highlight the importance of shaping the fate of self-renewed microglia and propose NRF2-mediated microglial repopulation as a potential pharmacological strategy for the treatment of tauopathies., This work was supported by the Spanish Ministry of Science, Innovation and Universities (PDC2022-133809-I00 and PID2021- 125986OB-I00 to MGL; PID2021-122650OB-I00 to MIRF; PID2022- 139936OA-I00 to EN and FPU20/03747 fellowship to LV); and the General Council for Research and Innovation of the Community of Madrid (P2022/BMD-7230 to MGL and 2020-T1/BMD-19886 to ET)., Peer reviewed